CAJ | 학술논문

乏氧是多数实体瘤的固有特征之一,可增加肿瘤细胞对放化疗的耐受性、促使肿瘤血管生成,是重要的不良预后因素.靶向杀伤肿瘤内的乏氧细胞成为肿瘤治疗的热点.生物还原性药物可通过特定的还原反应激活为细胞毒性代谢产物进而杀伤乏氧肿瘤细胞,而小分子靶点抑制剂则选择性地作用于乏氧途径中的关键环节,二者为肿瘤的乏氧靶向治疗开辟了新的途径.
핍양시다수실체류적고유특정지일,가증가종류세포대방화료적내수성、촉사종류혈관생성,시중요적불량예후인소.파향살상종류내적핍양세포성위종류치료적열점.생물환원성약물가통과특정적환원반응격활위세포독성대사산물진이살상핍양종류세포,이소분자파점억제제칙선택성지작용우핍양도경중적관건배절,이자위종류적핍양파향치료개벽료신적도경.
Hypoxia is an inherent feature of the majority of solid tumors,which can increase the resistance of tumor cells to radiotherapy and chemotherapy,promote tumor angiogenesis and lead to poor prognosis.Therefore,targeting the hypoxic tumor cells has become a spot in cancer therapy.Bioreduction drugs can be activated by a specific reduction to become cytotoxic metabolites,thus killing hypoxic tumor cells,while small molecular targeting inhibitors can selectively act on the key point of hypoxia pathway.They have paved a new way for hypoxia targeted therapy.